Physician profile
Jay I Freid
NPI 1649277005
$7,879.91
in general payments reported to CMS, 2019-2025
51 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,690 · 2020: $560 · 2021: $999 · 2022: $1,673 · 2023: $1,407 · 2024: $1,242 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,957.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $675.08 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $498.72 | 2022 | |
| Amgen INC. | $439.73 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $392.32 | 2019-2024 | Ajovy |
| Jazz Pharmaceuticals INC. | $380.36 | 2019-2025 | |
| Biogen, INC. | $334.41 | 2021-2023 | Vumerity, Tysabri |
| Avanir Pharmaceuticals, INC. | $331.65 | 2019-2022 | |
| Pfizer INC. | $305.75 | 2019-2024 | |
| Lilly USA, LLC | $301.22 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Ipsen Biopharmaceuticals, INC | $260.26 | 2019-2022 | |
| Eisai INC. | $254.39 | 2019-2023 | |
| Argenx US, INC. | $240.37 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $216.68 | 2021-2025 | Vyepti, Rexulti |
| Celgene Corporation | $193.51 | 2021-2024 | Zeposia |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Freid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.